Skip to playerSkip to main content
  • 5 weeks ago
A team of scientists at the University of Michigan has discovered a compound sourced from gut bacteria that has the potential to enhance cancer immunotherapy. The investigation centered around 3,4-dihydroxybenzoic acid (DHB), a metabolite formed when gut microbes digest dietary fiber. In experiments involving mouse models of melanoma, colorectal cancer, and breast cancer, an oral DHB prodrug paired with immune checkpoint therapy successfully eliminated tumors and fostered long-lasting immune memory. Additionally, the study indicated that DHB could enhance CAR T-cell therapy. These findings, published in Nature Nanotechnology, are still in the preclinical phase, with human trials required to assess the efficacy of this strategy in patients.
Disclosure:This video contains stock footage and content created or enhanced using Ai-assisted tools ai-generated

Category

🗞
News
Transcript
00:00University of Michigan researchers have found a gut compound that may boost cancer immunotherapy.
00:05The compound is called DHB. It is made by gut bacteria when they break down dietary fiber.
00:11Researchers found DHB helps T-cells become memory cells. These cells can keep fighting tumors for
00:17longer. The team also created an oral drug form of DHB. This was designed to help the body absorb
00:23it better. Researchers tested it in mice with three cancers. These included melanoma,
00:29colorectal cancer, and breast cancer. Combined with checkpoint therapy, the treatment eradicated
00:34the tumors. The mice also developed immune memory. That helped protect them against the tumors
00:40returning. DHB also improved CAR T-cell therapy in the study. But there is an important limitation.
00:46The results have only been shown in mice so far. Human trials are needed to see if the treatment
00:51works in patients. Disclosure. This video contains stock footage and content created or enhanced
00:56using AI-assisted tools AI-generated.

Recommended